The European Survey of Breakthrough Cancer Pain is continuing to recruit patients in Germany and Ireland and will expand into Austria, Belgium, Czech Republic, Finland, France, Greece, the Netherlands, Norway, Portugal, Spain and Switzerland to provide health care professionals across Europe with patient insights on the management of breakthrough cancer pain.
Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone in the company's growth strategy.
Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.
Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of EUR 3.4 billion and an adjusted EBITDA of EUR 1.2 billion.
For more information please visit http://www.nycomed.com
1. Davies A et al. European survey of oncology patient's experience of breakthrough cancer pain: UK, SE and DK results. Poster presented at EFIC 2009.
About the survey - First phase of an ongoing, multicentre observational study - First five countries include: UK, Sweden, Denmark, Germany, Ireland - 11 palli
Copyright©2009 PR Newswire.
All rights reserved